Drug Trial Radar · NCT06741150
NWRD09 for HPV-16 Positive and HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer Patients.
Last checked: Nov 19, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
18
Planned (sponsor's estimate)
Start
Jun 24, 2024
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Newish Technology (Beijing) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 18, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open label, two cohorts, multi-center clinical study to evaluate the safety and efficacy of HPV-16 targeted mRNA vaccine (NWRD09) in HPV-16 positive and HPV-16 related cervical, vaginal, and vulvar intraepithelial neoplasia (LSIL and HSIL) patients (cohort A) and HPV-16 related cervical cancer patients (cohort B).
Conditions
- Intraepithelial Neoplasia
- Cervical Cancer
Interventions
NWRD09 administered by intramuscular injectionBiological
Intramuscular injection administration was carried out according to the protocol design.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety(Cohort A and B)Time frame: Within 21 days of the first dosing
- Dose-limiting toxicity (DLT) (Cohort A and B)Time frame: Within 21 days of the first dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.